Esperion Long Term Data On Cholesterol Medication's Ability To Cut Cardiovascular Risk Fails To Impress Investors - Yahoo Finance
- Esperion Long Term Data On Cholesterol Medication's Ability To Cut Cardiovascular Risk Fails To Impress Investors Yahoo Finance
- Can’t take statins? New pill cuts cholesterol, heart attacks syracuse.com
- Here's a new medicine that may address statin intolerance 13News Now
- Esperion Therapeutics stock slumps 22% premarket as data from study of cholesterol-lowering drug fail to impress investors MarketWatch
- With heart attack data in its favor, what's next for Esperion? - STAT STAT
- View Full Coverage on Google News